Research programme: anti-EGFR natural killer cell therapy - Cytea Bio
Alternative Names: Pin™ anti-EGFR + eNK - Cytea BioLatest Information Update: 18 Apr 2024
Price :
$50 *
At a glance
- Originator CYTEA BIO
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glioblastoma
- Research Solid tumours
Most Recent Events
- 18 Apr 2024 Early research in Solid tumours in France (Parenteral), prior to April 2024 (Cytea Bio pipeline, April 2024)
- 05 Dec 2023 Preclinical trials in Glioblastoma in France (Parenteral), prior to December 2023 (Cytea Bio pipeline, December 2023)